Press releases

FLAGGING OF A TRANSACTION BETWEEN PMDRS IN EEVIA HEALTH PLC

Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc, ("Eevia" or "The Company") has sold 112 782 shares in The Company to Harri Salo, the Chief Manufacturing Officer (CMO) of Eevia.

Stein Ulve, CEO of Eevia has sold 112 782 shares in Eevia to Harri Salo, the CMO of the Company.

Stein Ulve had 2 397 496 shares before the sale and now has 2 284 714 shares.

Harri Salo had no shares before the purchase and now owns 112 782 shares.

The two managers will after the transaction hold 7,53% and 0,37%, respectively, of The Company's outstanding shares. Stein Ulve and Harri Salo have no options or other financial instruments as part of any incentive system in Eevia.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com                      

Telephone: +358 400 22 5967    

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth. 

2023-01-18
Regulatory

Eevia Health ("Eevia" or "The Company") received a sales order from a US customer for the elderberry extract Feno-Sambucus™ 7 Organic for a value of just over USD 200k or EUR 187k.

2023-01-16
Regulatory

Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc, ("Eevia" or "The Company") has sold 112 782 shares in The Company to Harri Salo, the Chief Manufacturing Officer (CMO) of Eevia.

2023-01-13

Due to a misjudgement, the MAR label was added to the original press release. The press release did not contain any insider information or other reason for the MAR label. This press release is a correction without the MAR label. 

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.

2023-01-13
Regulatory

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.

2022-12-19
Regulatory

Eevia Health Plc's ("Eevia" or "the Company") preferential rights issue has now been registered with the Finnish Trade Register. Paid Subscription Shares (Swedish: BTA) will thus be replaced by ordinary shares. The last day for trading with BTA on Spotlight Stock Market is 22 December 2022, and new shares are expected to be booked into the respective custodian/VP account on 29 December 2022.

2022-12-05
Regulatory

Stein Ulve, the CEO of Eevia Health Plc, ("Eevia" or "The Company"), subscribed for 489 996 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed. Stein Ulve had 1 907 500 subscription rights, but he subscribed for 489 996 shares. Consequently, he was diluted under the flagging threshold of 10%.

2022-12-05
Regulatory

Eevia Health Plc ("the Company" or "Eevia") has become aware that Marizoe Actives S.L. from Madrid, Spain has subscribed for 1 517 459 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed, leading to a new total of shares of 30 349 371. Marizoe Actives S.L. had no shares before the issue and with the subscription, Marizoe has 5.01% of the new outstanding shares.

2022-12-01
Regulatory

Eevia Health ("Eevia" or "The Company") received a start order for the Feno-Sambucus™ worth SEK 110 000 from its Australian distributor Ingredient Plus. The order is a new start order for an Australian brand owner.

2022-11-30
Regulatory

Eevia Health Plc's ("Eevia" or "The Company") has received a 41 KEUR sales order for Bilberry extract from its distributor in France Natural Ingredients.

2022-11-30

Eevia Health has commissioned a new High-Performance Liquid Chromatography (HPLC) analytical equipment from Shimadzu, which significantly increases the capacity to undertake analyses of polyphenols.

1
2
...
8
>>